drugset / Trial / NCT01424033
A Clinical Trial for CTD-ILD Treatment
NaSingle-groupOpen-labelTreatment
Summary
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
Timeline
- Start
- 2011-12
- Primary completion
- 2013-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 600 mg | Oral |